Compare American Electric Power Company Inc (AEP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs TG Therapeutics Inc — how do they compare? American Electric Power Company Inc trades at $123.69 (market cap $67.28B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: American Electric Power Company Inc is far larger — about 8.8× TG Therapeutics Inc's market cap, and American Electric Power Company Inc pays a 3.07% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AEP | TGTX | |
|---|---|---|
Market Cap | $67.28B | $7.64B |
Sector | Utilities | Health |
52-Week High | $138.69 | $59.06 |
52-Week Low | $106.44 | $26.94 |
Enterprise Value | $120.17B | $7.84B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $124.17, up 1.08% today, with a bearish technical signal but strong fundamentals. Recent Q2 2026 EPS missed estimates at $1.36 versus $1.48 expected, yet revenue grew 7% year-over-year. The company raised 2026 operating EPS guidance to $6.25–$6.55, supported by a $78 billion capital plan and 69 GW of contracted load growth. Analyst consensus is bullish with a $140.89 price target, and dividends remain stable with a $0.95 payment scheduled for September 2026.
Outlook is positive due to robust demand from data centers and regulatory progress, but risks include high debt levels and interest expenses. The stock offers growth potential from AI-driven electricity demand, though valuation premiums and execution risks warrant caution. Near-term support lies at $121, with resistance at $126.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
